Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$329K Buy
6,833
+1,163
+21% +$59.4K ﹤0.01% 1221
2026
Q2
$297K Buy
5,670
+454
+9% +$24K ﹤0.01% 1240
2026
Q1
$288K Sell
5,216
-13,437
-72% -$728K ﹤0.01% 1176
2025
Q4
$915K Sell
18,653
-4,539
-20% -$212K 0.01% 742
2025
Q3
$1M Buy
23,192
+1,364
+6% +$53.3K 0.01% 688
2025
Q2
$838K Buy
+21,828
New +$834K 0.01% 686
2023
Q3
– Sell
-114
Closed -$4K – 656
2023
Q2
$4K Hold
114
– – ﹤0.01% 621
2023
Q1
$4K Sell
114
-118
-51% -$4.13K ﹤0.01% 637
2022
Q4
$8K Hold
232
– – ﹤0.01% 603
2022
Q3
$7K Buy
232
+1
+0.4% +$38 ﹤0.01% 590
2022
Q2
$13K Buy
231
+3
+1% +$166 ﹤0.01% 558
2022
Q1
$12K Buy
+228
New +$12.4K ﹤0.01% 594

Other funds holding GSK

Benjamin Edwards's GSK Position: Q3 2026 in Review

Benjamin Edwards increased its GSK (GSK) stake by 21% in Q3 2026, buying an estimated $59.4K and bringing the position to 6,833 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #1221.

Benjamin Edwards first reported a position in GSK in Q1 2022 and has held it in 12 quarters since. The position peaked at $1M in Q3 2025. 854 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Benjamin Edwards held 6,833 shares of GSK worth $329K as of Q3 2026.
  • Benjamin Edwards bought 1,163 GSK shares in Q3 2026, an estimated $59.4K.
  • GSK made up ﹤0.01% of Benjamin Edwards's portfolio in Q3 2026, its #1221 holding.
  • Benjamin Edwards first reported a position in GSK in Q1 2022 and has held it in 12 quarters since.
  • Benjamin Edwards's GSK position peaked at $1M in Q3 2025.
  • 854 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Benjamin Edwards's 13F filing for Q3 2026, filed 12 Nov 2026.